Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujata Patil

Showing results (201-210 of 230) with videos related to

Pageof 23
Sort By:
Annals of Surgery|June 27, 2017
Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 PatientsMonica Morrow, Kimberly J Van Zee, Sujata Patil, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
JCO Oncology Practice|October 21, 2025
Impact of an Electronic Patient-Reported Outcome-Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD)Talya Salz, Emily V Dressler, Carol Kittel, et al.
JAMA Network Open|November 28, 2019
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNeil M Iyengar, Lillian M Smyth, Diana Lake, et al.
Clinical Breast Cancer|February 12, 2014
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerKomal Jhaveri, Sarat Chandarlapaty, Diana Lake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trialDarren R Feldman, Yasser Ged, Chung-Han Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerTiffany A Traina, Hope S Rugo, James F Caravelli, et al.
The Lancet. Oncology|July 19, 2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trialJulio Garcia-Aguilar, Oliver S Chow, David D Smith, et al.
European Urology|February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing NephrectomyMaria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
Pageof 23

Showing results (201-210 of 230) with videos related to

Sort By:
Pageof 23
Annals of Surgery|June 27, 2017
Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 PatientsMonica Morrow, Kimberly J Van Zee, Sujata Patil, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
JCO Oncology Practice|October 21, 2025
Impact of an Electronic Patient-Reported Outcome-Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD)Talya Salz, Emily V Dressler, Carol Kittel, et al.
JAMA Network Open|November 28, 2019
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNeil M Iyengar, Lillian M Smyth, Diana Lake, et al.
Clinical Breast Cancer|February 12, 2014
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerKomal Jhaveri, Sarat Chandarlapaty, Diana Lake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trialDarren R Feldman, Yasser Ged, Chung-Han Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerTiffany A Traina, Hope S Rugo, James F Caravelli, et al.
The Lancet. Oncology|July 19, 2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trialJulio Garcia-Aguilar, Oliver S Chow, David D Smith, et al.
European Urology|February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing NephrectomyMaria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
Pageof 23